Seasoned healthcare professional brings experience in patient advocacy and community education to global rare disease nonprofit

Newport Beach, Calif. – January 23, 2024 – CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, today announced an addition to its executive team with the hiring of Senior Director of Community Engagement, Patricia Brown, MBA, BSN, R.N. This position plays a crucial role in CureDuchenne’s mission of improving the lives of individuals and families affected by Duchenne muscular dystrophy, championing the needs of the community and fostering relationships with external partners, caretakers and healthcare providers.

Patricia, a seasoned professional with over 15 years of experience in healthcare, has deep experience in advocacy, community education, and patient care. Most recently serving as Associate Director of Patient Engagement North America at PTC Therapeutics, Patricia excelled in supporting individuals with Duchenne muscular dystrophy and their caregivers. Her work involved understanding the needs and challenges of the community and leading cross-functional collaboration to identify and implement effective solutions for addressing disparities in care. She also brings expertise in working with patient advocacy organizations to facilitate patient access to resources such as external appeal assistance, family support, and community networking. Prior to PTC Therapeutics, Patricia served as a Senior Nurse Manager at Lash Group, where she designed and deployed pharmaceutical clinical support services for FDA- approved medications and led educational programs tailored to address emerging trends observed within the community. Patricia received her Master of Business Administration degree from Texas Women’s University and Bachelor of Science degree in nursing from Texas Tech University.

“Patricia Brown joining our team reinforces our commitment to not just finding a cure, but also to enhancing the quality of life for those affected by Duchenne muscular dystrophy,” said CureDuchenne founder and CEO Debra Miller. “Patricia’s deep understanding of patient needs and challenges, coupled with her experience in fostering collaborative solutions, will be instrumental in advancing our mission. We look forward to the positive changes and new perspectives Patricia will bring to CureDuchenne.”

CureDuchenne was founded by Debra and Paul Miller in 2003 after their son was diagnosed with Duchenne muscular dystrophy. The organization combines fundraising and venture philanthropy, identifying and investing donor dollars into promising research leading to transformative treatments for those living with Duchenne. CureDuchenne also provides resources and guidance for families affected by the fatal genetic neuromuscular disorder, which affects more than 300,000 individuals worldwide.

About CureDuchenne

Twenty years ago, CureDuchenne was created with one goal: to find and fund a cure for Duchenne muscular dystrophy, one of the most common and severe forms of muscular dystrophy. Today, CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne. CureDuchenne’s innovative venture philanthropy model has advanced transformative treatments for Duchenne muscular dystrophy, including 18 projects that advanced to human clinical trials and multiple projects to overcome the limitations of exon-skipping and gene therapy. In addition, CureDuchenne contributed early funding to the first FDA-approved Duchenne drug, pioneered the first and only Duchenne physical and occupational therapist certification program and created an innovative data-integrated biobank, accelerating research toward a cure. For more information on how to help raise awareness and funds needed for research, please visit cureduchenne.org or follow us on Facebook, Instagram, LinkedIn, and X.

---